Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells $786,200.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Wim Souverijns sold 20,000 shares of Pharvaris stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $39.31, for a total value of $786,200.00. Following the completion of the transaction, the insider directly owned 45,111 shares in the company, valued at $1,773,313.41. This represents a 30.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Wim Souverijns also recently made the following trade(s):

• On Tuesday, September 15th, Wim Souverijns sold 6,090 shares of Pharvaris stock. The stock was sold at an average price of $38.99, for a total value of $237,449.10.

Pharvaris Stock Performance

PHVS opened at $36.37 on Friday. The firm has a 50 day moving average price of $35.37 and a 200 day moving average price of $31.73. The company has a market cap of $2.38 billion, a PE ratio of -11.92 and a beta of -2.33. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $43.25.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, sell-side analysts predict that Pharvaris N.V. will post -3.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on PHVS shares. HSBC raised shares of Pharvaris to an “overweight” rating in a research report on Thursday, August 13th. UBS Group set a $79.00 price objective on Pharvaris in a research report on Wednesday, September 9th. Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Royal Bank Of Canada upped their target price on Pharvaris from $52.00 to $62.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $75.00 target price on shares of Pharvaris in a research note on Tuesday, September 8th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $59.87.

Institutional Investors Weigh In On Pharvaris

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PHVS. Quantbot Technologies LP purchased a new position in Pharvaris in the 2nd quarter valued at about $41,000. CoreCap Advisors LLC purchased a new stake in shares of Pharvaris during the second quarter worth about $93,000. Amundi increased its position in shares of Pharvaris by 12.0% during the first quarter. Amundi now owns 30,952 shares of the company’s stock worth $874,000 after acquiring an additional 3,312 shares during the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Pharvaris in the fourth quarter worth about $139,000. Finally, Sofinnova Investments Inc. lifted its stake in shares of Pharvaris by 0.7% in the fourth quarter. Sofinnova Investments Inc. now owns 745,169 shares of the company’s stock worth $20,678,000 after acquiring an additional 5,293 shares in the last quarter.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.